Strand Therapeutics News and Activities

View the org chart displaying its 23 main executives

Most searched biographies at Strand Therapeutics

• Jake Becraft, Chief Executive Officer and Director
• Jory Bell, Director
• Ala Alenazi, Director

Popular executive movements at Strand Therapeutics

• Kunal Bhatia has joined the company as Chief Financial Officer  (posted on April 30 2026).
• Jeb Keiper has joined the company as Independent Director  (posted on December 3 2025).
• Prashant Nambiar, who was Senior Vice President of Discovery and Translational Development, is promoted to Chief Scientific Officer  (posted on November 5 2025).

Click here to view some more movements at Strand Therapeutics

Create your alert
to follow the executive moves at Strand Therapeutics.

Strand Therapeutics has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Strand Therapeutics

• Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer
• Phase 1 dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors - Strand Therapeutics
• STX-003: Cancer Immunotherapy with systemic delivery of mRNA utilizing programmable genetic circuits for precise regulation of IL-12 expression and reduced toxicity - Strand Therapeutics
• Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
• STX-003: Utilizing Programmable Genetic Circuits for Tumor-Specific IL-12 Expression and Reduced Toxicity with Systemically Delivered mRNA - Strand Therapeutics
• STX-003: A Novel Systemically-Delivered mRNA-Based Cancer Therapy Utilizing a Programmable Genetic Circuit Platform for Tumor-Specific Protein Expression and Reduced Toxicity - Strand Therapeutics
• Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors
• Unlocking mRNA’s cancer-fighting potential
• Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors
• Delivering on the Promise of Personalized mRNA Therapeutics
• View more press releases Close

Social media about Strand Therapeutics

• Strand Therapeutics on Wikipedia, Google News & Yahoo Finance
• Strand Therapeutics on LinkedIn, X (Twitter) & YouTube